Mid-Tier Japanese Pharma See Flurry Of Licensing Activity Ahead Of Earnings Season
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's mid-tier pharma have had a fruitful week during and following the BioJapan partnering conference in Yokohama, announcing a number of deals with Japanese and Western biotechs as they continue to broaden their reach outside of Japan
You may also be interested in...
Lundbeck Establishes Shanghai Research Center To Find More Chinese Partnerships
Danish pharma Lundbeck A/S announced Oct. 14 that it established a research center in Shanghai to increase its footprint in the largest emerging market and better position itself for more partnerships in China
Lundbeck Establishes Shanghai Research Center To Find More Chinese Partnerships
Danish pharma Lundbeck A/S announced Oct. 14 that it established a research center in Shanghai to increase its footprint in the largest emerging market and better position itself for more partnerships in China
Kyowa Hakko Kirin Pins Rebound On KW-0761 For Oncology And Allergy Indications
TOKYO - Kyowa Hakko Kirin posted modest gains in its pharmaceutical business at its announcement of interim results as expectation rides on the eventual outcome of KW-0761, a humanized anti-CCR-4 monoclonal antibody being developed by Kyowa for hematological cancer applications in Japan and the U.S. and by licensing partner Amgen in the U.K. for allergy application